Recombinant Human Interleukin-2, Recombinant Human Interferon Alfa-2a, or Both in Metastatic Renal-Cell Carcinoma

1998967 citationsJournal Articlebronze Open Access

Authors

Sylvie Négrier · Centre Léon Bérard

Bernard Escudier · Institut Gustave Roussy

Christine Lasset · Centre Léon Bérard

Jean‐Yves Douillard

J. Savary · Centre Léon Bérard

Christine Chevreau · Institut Claudius Regaud

Alain Ravaud · Institut Bergonié

Abstract

Cytokines are active in a few patients with metastatic renal-cell carcinoma. The higher response rate and longer event-free survival obtained with a combination of cytokines must be balanced against the toxicity of such treatment.

Topics & Keywords

Renal cell carcinoma treatment Bladder and Urothelial Cancer Treatments Renal and related cancers

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 338, Issue 18, pp. 1272-1278

DOI: 10.1056/nejm199804303381805

Field-Weighted Citation Impact: 38.01